BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

Informacje na temat projektu

REMEDi4ALL

Identyfikator umowy o grant: 101057442

DOI

10.3030/101057442

Data podpisania przez KE 19 Maja 2022

Data rozpoczęcia 1 Września 2022

Data zakończenia 31 Sierpnia 2027

Finansowanie w ramach

• Health

Koszt całkowity

€ 22 561 532,00

Wkład UE

€ 22 561 532,00

Koordynowany przez

EATRIS ERIC
Netherlands

CORDIS oferuje możliwość skorzystania z odnośników do publicznie dostępnych publikacji i rezultatów projektów realizowanych w ramach programów ramowych HORYZONT.

Odnośniki do rezultatów i publikacji związanych z poszczególnymi projektami 7PR, a także odnośniki do niektórych konkretnych kategorii wyników, takich jak zbiory danych i oprogramowanie, są dynamicznie pobierane z systemu OpenAIRE .

Rezultaty

Documents, reports (6)

Report on AI tools and data resource

Report on existing AI tools and data resources carefully tested, ranked and classified for various repurposing applications.

Training landscape map

Report summarising existing information training and support in DR with publicfacing signposting to existing repurposing resources and trainings

Report on establishment of the Funders network

Documentation of commitment of funders that are motivated to join the Repurposing Funders Network, including Charter.

Report on the strategy and roadmap for collaboration with other synergies

This report will provide a guide of synergies with other projects and networks to be implemented during the project the methodological framework process and sources for the identification of projects with which to build synergies

Report on the 1st Annual Conference

Report on the 1st Annual Conference describing program highlights, attendees, interactions with key stakeholders and suggestions for agenda and organisation of next conference.

Report on services, expertise, barriers in the clinical development

Report describing the mapping of the clinical drug repruposing landscape identification of barriers gap analysis and blueprint report focusing on the clinical development

Publikacje

Peer reviewed articles (16)

Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia

Autorzy: Adnan Awad, Shady; Dufva, Olli; Klievink, Jay; Karjalainen, Ella; Ianevski, Aleksandr; Pietarinen, Paavo; Kim, Daehong; Potdar, Swapnil; Wolf, Maija; Lotfi, Kourosh; Aittokallio, Tero; Wennerberg, Krister; Porkka, Kimmo; Mustjoki, Satu
Opublikowane w: Cell Reports Medicine, 2024, ISSN 2666-3791
Wydawca: Elsevier
DOI: 10.1016/J.XCRM.2024.101521

Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta

Autorzy: Paul Arundel; Nick Bishop
Opublikowane w: Calcified Tissue International, 2024, ISSN 1432-0827
Wydawca: Springer Nature
DOI: 10.1007/S00223-024-01202-7

Robust scoring of selective drug responses for patient-tailored therapy selection

Autorzy: Yingjia Chen; Liye He; Aleksandr Ianevski; Pilar Ayuda-Durán; Swapnil Potdar; Jani Saarela; Juho J. Miettinen; Sari Kytölä; Susanna Miettinen; Mikko Manninen; Caroline A. Heckman; Jorrit M. Enserink; Krister Wennerberg; Tero Aittokallio
Opublikowane w: Nature Protocols, 2023, ISSN 1750-2799
Wydawca: Nature Portfolio
DOI: 10.1038/S41596-023-00903-X

Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol

Autorzy: Alfredo Budillon, Alessandra Leone, Eugenia Passaro, Lucrezia Silvestro, Francesca Foschini, Federica Iannelli, Maria Serena Roca, Marina Macchini, Francesca Bruzzese, Maria Laura Garcia Bermejo, Mercedes Rodriguez Garrote, Giampaolo Tortora, Michele Mile
Opublikowane w: BMC Cancer, 2024, ISSN 1471-2407
Wydawca: BioMed Central
DOI: 10.1186/S12885-024-12936-W

Improved Detection of Drug-Induced Liver Injury by Integrating Predicted<i>in vivo</i>and<i>in vitro</i>Data

Autorzy: Srijit Seal; Dominic P. Williams; Layla Hosseini-Gerami; Manas Mahale; Anne E. Carpenter; Ola Spjuth; Andreas Bender
Opublikowane w: Chemical Research in Toxicology, 2024, ISSN 1520-5010
Wydawca: American Chemical Society
DOI: 10.1021/ACS.CHEMRESTOX.4C00015

Nature Communications

Autorzy: Aleksandr Ianevski; Kristen Nader; Kyriaki Driva; Wojciech Senkowski; Daria Bulanova; Lidia Moyano-Galceran; Tanja Ruokoranta; Heikki Kuusanmäki; Nemo Ikonen; Philipp Sergeev; Markus Vähä-Koskela; Anil K. Giri; Anna Vähärautio; Mika Kontro; Kimmo Porkka; Esa Pitkänen; Caroline A. Heckman; Krister Wennerberg; Tero Aittokallio
Opublikowane w: Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones, 2024, ISSN 2041-1723
Wydawca: Springer Nature
DOI: 10.1038/S41467-024-52980-5

RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies

Autorzy: Aleksandr Ianevski; Aleksandr Kushnir; Kristen Nader; Mitro Miihkinen; Henri Xhaard; Tero Aittokallio; Ziaurrehman Tanoli
Opublikowane w: Briefings in Bioinformatics, 2024, ISSN 1477-4054
Wydawca: Oxford University Press
DOI: 10.1093/BIB/BBAE328

Cell Painting: a decade of discovery and innovation in cellular imaging

Autorzy: Seal, Srijit; Trapotsi, Maria-Anna; Spjuth, Ola; Singh, Shantanu; Carreras-Puigvert, Jordi; Greene, Nigel; Bender, Andreas; Carpenter, Anne E
Opublikowane w: Nature Methods, 2024, ISSN 1548-7105
Wydawca: Nature Portfolio
DOI: 10.17863/CAM.112378

Artificial intelligence for high content imaging in drug discovery

Autorzy: Jordi Carreras-Puigvert; Ola Spjuth
Opublikowane w: Current Opinion in Structural Biology, 2024, ISSN 1879-033X
Wydawca: Elsevier
DOI: 10.1016/J.SBI.2024.102842

HPR155 Drug Repurposing: Policy Barriers to Using Existing Pharmaceuticals in New Indications: Results of a Systematic Literature Review

Autorzy: Z Petykó, D Hosszú, M Csanádi, GD Obeng, D Ameyaw, K Gyöngyösi, HG van der Meer, P Pantziarka, Z Kalo, A Inotai
Opublikowane w: Value in Health, Numer 27, 2024, ISSN 1098-3015
Wydawca: Elsevier BV
DOI: 10.1016/J.JVAL.2024.10.1581

From pixels to phenotypes: Integrating image-based profiling with cell health data as BioMorph features improves interpretability

Autorzy: Srijit Seal; Jordi Carreras-Puigvert; Shantanu Singh; Anne E. Carpenter; Ola Spjuth; Andreas Bender
Opublikowane w: Molecular Biology of the Cell, 2024, ISSN 1939-4586
Wydawca: American Society for Cell Biology
DOI: 10.1091/MBC.E23-08-0298

Attention-based approach to predict drug-target interactions across seven target superfamilies

Autorzy: Aron Schulman; Juho Rousu; Tero Aittokallio; Ziaurrehman Tanoli
Opublikowane w: Bioinformatics, 2024, ISSN 1367-4811
Wydawca: Oxford University Press
DOI: 10.1093/BIOINFORMATICS/BTAE496

Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?

Autorzy: Claudia Fuchs; Peter A. C. ‘t Hoen; Annelieke R. Müller; Annelieke R. Müller; Annelieke R. Müller; Friederike Ehrhart; Clara D. M. Van Karnebeek; Clara D. M. Van Karnebeek; Clara D. M. Van Karnebeek
Opublikowane w: Frontiers in Medicine, 2024, ISSN 2296-858X
Wydawca: Frontiers Media
DOI: 10.3389/FMED.2024.1425038

Exploring SureChEMBL from a drug discovery perspective

Autorzy: Yojana Gadiya; Simran Shetty; Martin Hofmann-Apitius; Philip Gribbon; Andrea Zaliani
Opublikowane w: Nature Scientific Data, 2024, ISSN 2052-4463
Wydawca: Nature Portfolio
DOI: 10.1038/S41597-024-03371-4

Drug repurposing for rare: progress and opportunities for the rare disease community

Autorzy: Anneliene Hechtelt Jonker; Anneliene Hechtelt Jonker; Daniel O’Connor; Daniel O’Connor; Maria Cavaller-Bellaubi; Maria Cavaller-Bellaubi; Christine Fetro; Christine Fetro; Maria Gogou; Maria Gogou; Peter A. C. ’T Hoen; Peter A. C. ’T Hoen; Martin de Kort; Martin de Kort; Heather Stone; Heather Stone; Nivedita Valentine; Nivedita Valentine; Anna Maria Gerdina Pasmooij; Anna Maria Gerdina Pasmooij
Opublikowane w: Frontiers in Medicine, 2024, ISSN 2296-858X
Wydawca: Frontiers Media
DOI: 10.3389/FMED.2024.1352803

Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA Drug-Induced Cardiotoxicity Rank

Autorzy: Srijit Seal; Ola Spjuth; Layla Hosseini-Gerami; Miguel García-Ortegón; Shantanu Singh; Andreas Bender; Anne E. Carpenter
Opublikowane w: Journal of Chemical Information and Modeling, 2024, ISSN 1520-5142
Wydawca: American Chemical Society
DOI: 10.1021/ACS.JCIM.3C01834

Other (1)

REMEDi4ALL - Standard Operating Guideline - Fair Data Assessment

Autorzy: Gadiya, Yojana; Zaliani, Andrea
Opublikowane w: Zenodo, 2025
Wydawca: Zenodo
DOI: 10.5281/ZENODO.14605175